LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction
JAMA 10.1001/jama.2026.17302August 29, 2026 at 2:30 AM EDT
In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year. However, no clinical benefit was detected during the first year of follow-up, arguing against clinically meaningful acute pleiotropic effects of PCSK9 inhibitors in addition to standard care.
Meeting Information: ESC 2026
This paper will be presented during European Society of Cardiology Congress in Munich, Germany.
Local Embargo Time: 8:30 A.M. CEST.
ESC Presentation: Gilles Montalescot will simultaneously present the findings during the Hot Line 2 session in the Main Auditorium.
Related Content: This paper has an accompanying editorial.
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Need more information? Contact us.